000276826 001__ 276826
000276826 005__ 20250318091451.0
000276826 0247_ $$2doi$$a10.1007/s00415-025-12915-6
000276826 0247_ $$2pmid$$apmid:39985674
000276826 0247_ $$2pmc$$apmc:PMC11846738
000276826 0247_ $$2ISSN$$a0367-004X
000276826 0247_ $$2ISSN$$a0012-1037
000276826 0247_ $$2ISSN$$a0340-5354
000276826 0247_ $$2ISSN$$a1432-1459
000276826 037__ $$aDZNE-2025-00339
000276826 041__ $$aEnglish
000276826 082__ $$a610
000276826 1001_ $$00000-0001-9078-1565$$aReese, René$$b0
000276826 245__ $$aInvasive therapies for Parkinson's disease: an adapted excerpt from the guidelines of the German Society of Neurology.
000276826 260__ $$a[Darmstadt]$$bSteinkopff$$c2025
000276826 3367_ $$2DRIVER$$aarticle
000276826 3367_ $$2DataCite$$aOutput Types/Journal article
000276826 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1740396245_22203$$xReview Article
000276826 3367_ $$2BibTeX$$aARTICLE
000276826 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000276826 3367_ $$00$$2EndNote$$aJournal Article
000276826 520__ $$aParkinson's disease (PD) is characterized by hypokinetic motor symptoms, tremor, and various non-motor symptoms with frequent fluctuations of symptoms in advanced disease stages. Invasive therapies, such as deep brain stimulation (DBS), ablative therapies, and continuous subcutaneous or intrajejunal delivery of dopaminergic drugs via pump therapies are available for the management of this complex motor symptomatology and may also impact non-motor symptoms. The recent update of the clinical guideline on PD by the German Neurological Society (Deutsche Gesellschaft für Neurologie e.V.; DGN) offers clear guidance on the indications and applications of these treatment options.The guideline committee formulated diagnostic questions for invasive therapies and structured them according to the PICOS framework (Population-Intervention-Comparisons-Outcome-Studies). A systematic literature review was conducted. Questions were addressed using the findings from the literature review and consented by the guideline committee.Specific recommendations are given regarding (i) the optimal timing for starting invasive therapies, (ii) the application of DBS, (iii) the use of pump therapies in advanced PD, (iv) the indications for ablative procedures, and (iv) selecting the most appropriate therapy according to individual patient characteristics.This review is an adapted excerpt of the chapters on the use of invasive therapies in PD of the novel German guideline on PD. Clear recommendations on the use of treatment options for advanced PD are provided.
000276826 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000276826 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000276826 650_7 $$2Other$$aAblation
000276826 650_7 $$2Other$$aDeep brain stimulation (DBS)
000276826 650_7 $$2Other$$aInvasive therapies
000276826 650_7 $$2Other$$aParkinson’s disease
000276826 650_7 $$2Other$$aPump therapy
000276826 650_2 $$2MeSH$$aHumans
000276826 650_2 $$2MeSH$$aParkinson Disease: therapy
000276826 650_2 $$2MeSH$$aDeep Brain Stimulation: standards
000276826 650_2 $$2MeSH$$aNeurology: standards
000276826 650_2 $$2MeSH$$aNeurology: methods
000276826 650_2 $$2MeSH$$aGermany
000276826 650_2 $$2MeSH$$aPractice Guidelines as Topic: standards
000276826 650_2 $$2MeSH$$aSocieties, Medical: standards
000276826 7001_ $$0P:(DE-2719)2810825$$aKoeglsperger, Thomas$$b1$$eFirst author$$udzne
000276826 7001_ $$aSchrader, Christoph$$b2
000276826 7001_ $$aTönges, Lars$$b3
000276826 7001_ $$aDeuschl, Günther$$b4
000276826 7001_ $$0P:(DE-2719)2811089$$aKühn, Andrea$$b5$$udzne
000276826 7001_ $$aKrack, Paul$$b6
000276826 7001_ $$aSchnitzler, Alfons$$b7
000276826 7001_ $$0P:(DE-2719)9000306$$aStorch, Alexander$$b8$$udzne
000276826 7001_ $$aTrenkwalder, Claudia$$b9
000276826 7001_ $$0P:(DE-2719)2811373$$aHöglinger, Günter U$$b10$$udzne
000276826 7001_ $$aGroup, German Parkinson‘s Guideline$$b11$$eCollaboration Author
000276826 773__ $$0PERI:(DE-600)1421299-7$$a10.1007/s00415-025-12915-6$$gVol. 272, no. 3, p. 219$$n3$$p219$$tJournal of neurology$$v272$$x0367-004X$$y2025
000276826 8564_ $$uhttps://pub.dzne.de/record/276826/files/DZNE-2025-00339.pdf$$yOpenAccess
000276826 8564_ $$uhttps://pub.dzne.de/record/276826/files/DZNE-2025-00339.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000276826 909CO $$ooai:pub.dzne.de:276826$$popenaire$$popen_access$$pVDB$$pdriver$$pdnbdelivery
000276826 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810825$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b1$$kDZNE
000276826 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)2811089$$aExternal Institute$$b5$$kExtern
000276826 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000306$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b8$$kDZNE
000276826 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811373$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b10$$kDZNE
000276826 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000276826 9141_ $$y2025
000276826 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-10
000276826 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-10
000276826 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-10
000276826 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-10
000276826 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-10
000276826 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000276826 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ NEUROL : 2022$$d2024-12-10
000276826 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-10
000276826 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2024-12-10$$wger
000276826 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-10
000276826 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-10
000276826 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-10
000276826 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bJ NEUROL : 2022$$d2024-12-10
000276826 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-10
000276826 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000276826 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2024-12-10$$wger
000276826 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-10
000276826 9201_ $$0I:(DE-2719)1111015$$kClinical Research (Munich)$$lClinical Research (Munich)$$x0
000276826 9201_ $$0I:(DE-2719)5000014$$kAG Storch$$lNon-Motor Symptoms in Parkinson's disease$$x1
000276826 980__ $$ajournal
000276826 980__ $$aVDB
000276826 980__ $$aUNRESTRICTED
000276826 980__ $$aI:(DE-2719)1111015
000276826 980__ $$aI:(DE-2719)5000014
000276826 9801_ $$aFullTexts